Circulating adipokines in children with nonalcoholic fatty liver disease: possible noninvasive diagnostic markers
- PMID: 28655985
- PMCID: PMC5480001
- DOI: 10.20524/aog.2017.0148
Circulating adipokines in children with nonalcoholic fatty liver disease: possible noninvasive diagnostic markers
Abstract
Background: The growing obesity pandemic is the leading cause for increasing prevalence of nonalcoholic fatty liver disease (NAFLD) in children. Histopathological evaluation of the liver remains the gold standard for NAFLD diagnosis, but it is an invasive procedure with a low but real risk of morbidity and mortality. The current study evaluated circulating chemerin and adiponectin as possible noninvasive diagnostic markers for NAFLD in obese non-diabetic children.
Methods: A prospective case-control study was conducted, which included 101 obese children with biopsy-proven NAFLD and 57 age- and sex-matched controls. The overall mean age of the children was 10.08±3.12 years. All underwent a full clinical assessment, routine laboratory investigation, and abdominal ultrasound. Homeostatic model assessment-insulin resistance was calculated and circulating chemerin and adiponectin were evaluated using ELISA.
Results: Elevated serum chemerin and decreased serum adiponectin were significantly associated with an increased likelihood of exhibiting NAFLD. Receiver operator characteristic curve analysis for differentiation of NAFLD patients from those in the control group demonstrated that chemerin, at a cutoff value of 186.7 ng/mL, yielded a sensitivity and specificity of 56.44% and 87.72% respectively (P<0.001), whereas adiponectin, at a cutoff value of 2.4 µg/mL, had a sensitivity and specificity of 74.26% and 3.51% respectively (P<0.001). Furthermore, body mass index, aspartate transaminase, alanine transaminase, triglycerides, and gamma-glutamyl transferase had significant positive correlations with chemerin and significant negative correlations with adiponectin (P≤0.001).
Conclusion: Circulating chemerin and adiponectin could serve as simple noninvasive diagnostic markers for NAFLD in non-diabetic obese children.
Keywords: Diagnosis; nonalcoholic fatty liver disease; noninvasive; obese children.
Conflict of interest statement
Conflict of Interest: None
Figures


Similar articles
-
Irisin in patients with nonalcoholic fatty liver disease.Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013. Epub 2013 Oct 18. Metabolism. 2014. PMID: 24140091
-
Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.World J Gastroenterol. 2013 Jul 7;19(25):4007-14. doi: 10.3748/wjg.v19.i25.4007. World J Gastroenterol. 2013. PMID: 23840146 Free PMC article.
-
Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.J Gastroenterol Hepatol. 2022 Oct;37(10):1853-1864. doi: 10.1111/jgh.15926. Epub 2022 Jul 15. J Gastroenterol Hepatol. 2022. PMID: 35748302
-
Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.Ital J Pediatr. 2014 Nov 17;40:84. doi: 10.1186/s13052-014-0084-4. Ital J Pediatr. 2014. PMID: 25399407 Free PMC article.
-
Adipokines in nonalcoholic fatty liver disease.Metabolism. 2016 Aug;65(8):1062-79. doi: 10.1016/j.metabol.2015.11.006. Epub 2015 Nov 24. Metabolism. 2016. PMID: 26725002 Review.
Cited by
-
Aerobic exercise decreases chemerin/CMKLR1 in the serum and peripheral metabolic organs of obesity and diabetes rats by increasing PPARγ.Nutr Metab (Lond). 2019 Mar 5;16:17. doi: 10.1186/s12986-019-0344-9. eCollection 2019. Nutr Metab (Lond). 2019. PMID: 30873215 Free PMC article.
-
Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.Front Endocrinol (Lausanne). 2021 Apr 13;12:663351. doi: 10.3389/fendo.2021.663351. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33927697 Free PMC article.
-
Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management.Pediatric Health Med Ther. 2019 Aug 23;10:89-97. doi: 10.2147/PHMT.S188989. eCollection 2019. Pediatric Health Med Ther. 2019. PMID: 31692530 Free PMC article.
-
Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm.Rom J Morphol Embryol. 2020 Oct-Dec;61(4):1023-1031. doi: 10.47162/RJME.61.4.04. Rom J Morphol Embryol. 2020. PMID: 34171051 Free PMC article. Review.
-
Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.J Diabetes Metab Disord. 2023 Jan 28;22(1):83-95. doi: 10.1007/s40200-023-01187-4. eCollection 2023 Jun. J Diabetes Metab Disord. 2023. PMID: 37255767 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources